Crinetics Pharmaceuticals presented positive Phase 2 trial results for atumelnant, an oral ACTH receptor antagonist, showing it effectively lowers androgen levels and allows reduction of glucocorticoid doses in adults with classic congenital adrenal hyperplasia (CAH). The drug also showed promising results in a Phase 1b/2a trial for ACTH-dependent Cushing's syndrome by rapidly reducing cortisol levels. Atumelnant was well tolerated with no serious adverse events reported. These findings support advancing atumelnant into late-stage clinical trials, including ongoing Phase 3 studies in both adult and pediatric populations, potentially offering a simpler, effective oral treatment for these endocrine disorders.
Stock and oil futures are set to begin trading as investors await the signing of a deal to end the Iran war, which President Donald Trump had promised would happen on Sunday but has not yet occurred. The anticipation around this agreement is influenc...
Solana (SOL) topped major cryptocurrencies with a 5.58% weekly gain, trading near $67–$70, a critical technical zone that could dictate its near-term trend. The rise is supported by increased activity in tokenized assets and real-world asset products...
Sui blockchain has processed nearly $65 billion in stablecoin transactions since June 10, following a protocol update that eliminated fees for stablecoin transfers. This fee removal, aimed at simplifying B2B payments and retail use, has boosted trans...
XRP is trading around $1.14 with a 29.5% drop in volume, reflecting cautious investor sentiment amid uncertainty over U.S. Federal Reserve policies and the ongoing Ripple-SEC legal case. The token's market cap stands at about $70.6 billion, maintaini...
Strategy sold a small amount of Bitcoin (32 BTC) but quickly bought back a much larger amount (1,550 BTC), signaling a shift from a strict 'never sell' stance to active treasury management. This approach highlights the importance of balance sheet res...
